Net Income (Loss) Attributable to Parent in USD of Tvardi Therapeutics, Inc. from 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Tvardi Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2012 to Q3 2025.
  • Tvardi Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$5.53M, a 0.25% decline year-over-year.
  • Tvardi Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$65.1M, a 32.8% decline year-over-year.
  • Tvardi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$70.9M, a 40.2% increase from 2023.
  • Tvardi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$119M, a 38.7% decline from 2022.
  • Tvardi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$85.5M, a 3.36% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Tvardi Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$65.1M -$5.53M -$14K -0.25% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025
Q2 2025 -$65.1M $4.17M +$11.1M 01 Apr 2025 30 Jun 2025 10-Q 13 Nov 2025
Q1 2025 -$76.2M -$9.58M -$5.38M -128% 01 Jan 2025 31 Mar 2025 10-Q 13 Nov 2025
Q4 2024 -$70.9M -$54.2M -$21.8M -67.5% 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025
Q3 2024 -$49M -$5.51M +$22.5M +80.3% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025
Q2 2024 -$71.5M -$6.98M +$24.5M +77.8% 01 Apr 2024 30 Jun 2024 10-Q 13 Nov 2025
Q1 2024 -$96.1M -$4.2M +$22.5M +84.2% 01 Jan 2024 31 Mar 2024 10-Q 13 Nov 2025
Q4 2023 -$119M -$32.3M -$2M -6.59% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025
Q3 2023 -$117M -$28M -$4.85M -20.9% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 -$112M -$31.5M -$27.3M -648% 01 Apr 2023 30 Jun 2023 10-Q 14 Nov 2024
Q1 2023 -$84.4M -$26.7M +$1.08M +3.91% 01 Jan 2023 31 Mar 2023 10-Q 14 Nov 2024
Q4 2022 -$85.5M -$30.3M +$3.04M +9.12% 01 Oct 2022 31 Dec 2022 10-K 11 Mar 2025
Q3 2022 -$88.5M -$23.2M -$22.2M -2188% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 -$66.4M -$4.21M +$26.5M +86.3% 01 Apr 2022 30 Jun 2022 10-Q 13 Nov 2023
Q1 2022 -$92.9M -$27.7M -$4.45M -19.1% 01 Jan 2022 31 Mar 2022 10-Q 13 Nov 2023
Q4 2021 -$88.4M -$33.4M -$112M -142% 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2024
Q3 2021 $23.9M -$1.01M +$15.5M +93.9% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 $8.35M -$30.7M -$5.68M -22.6% 01 Apr 2021 30 Jun 2021 10-Q 07 Nov 2022
Q1 2021 $14M -$23.3M +$5.62M +19.4% 01 Jan 2021 31 Mar 2021 10-Q 07 Nov 2022
Q4 2020 $8.41M $78.9M +$108M 01 Oct 2020 31 Dec 2020 10-K 25 Feb 2021
Q3 2020 -$99.1M -$16.5M +$16.3M +49.7% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021
Q2 2020 -$115M -$25.1M -$2.11M -9.18% 01 Apr 2020 30 Jun 2020 10-Q 08 Nov 2021
Q1 2020 -$113M -$28.9M -$6.96M -31.7% 01 Jan 2020 31 Mar 2020 10-Q 08 Nov 2021
Q4 2019 -$106M -$28.6M -$7.96M -38.5% 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2021
Q3 2019 -$98.4M -$32.8M -$13.4M -69.3% 01 Jul 2019 30 Sep 2019 10-K 25 Feb 2021
Q2 2019 -$85M -$23M -$5.77M -33.5% 01 Apr 2019 30 Jun 2019 10-K 25 Feb 2021
Q1 2019 -$79.2M -$22M -$5.19M -31% 01 Jan 2019 31 Mar 2019 10-K 25 Feb 2021
Q4 2018 -$74M -$20.7M -$6.48M -45.7% 01 Oct 2018 31 Dec 2018 10-K 27 Feb 2020
Q3 2018 -$67.5M -$19.4M -$6.96M -55.9% 01 Jul 2018 30 Sep 2018 10-K 27 Feb 2020
Q2 2018 -$60.6M -$17.2M -$7.89M -84.9% 01 Apr 2018 30 Jun 2018 10-K 27 Feb 2020
Q1 2018 -$52.7M -$16.8M +$5.44M +24.5% 01 Jan 2018 31 Mar 2018 10-K 27 Feb 2020
Q4 2017 -$58.1M -$14.2M +$7.79M +35.5% 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2019
Q3 2017 -$65.9M -$12.4M -$902K -7.82% 01 Jul 2017 30 Sep 2017 10-K 12 Mar 2019
Q2 2017 -$65M -$9.3M +$3.78M +28.9% 01 Apr 2017 30 Jun 2017 10-K 12 Mar 2019
Q1 2017 -$68.8M -$22.2M -$11.5M -108% 01 Jan 2017 31 Mar 2017 10-K 12 Mar 2019
Q4 2016 -$57.3M -$22M -$12.4M -131% 01 Oct 2016 31 Dec 2016 10-K 15 Mar 2018
Q3 2016 -$44.8M -$11.5M -$6.76M -141% 01 Jul 2016 30 Sep 2016 10-K 15 Mar 2018
Q2 2016 -$38.1M -$13.1M -$7.39M -130% 01 Apr 2016 30 Jun 2016 10-K 15 Mar 2018
Q1 2016 -$30.7M -$10.7M -$6M -128% 01 Jan 2016 31 Mar 2016 10-K 15 Mar 2018
Q4 2015 -$24.7M -$9.53M -$5.36M -128% 01 Oct 2015 31 Dec 2015 10-K 10 Mar 2017
Q3 2015 -$19.3M -$4.79M +$1.76M +26.9% 01 Jul 2015 30 Sep 2015 10-K 10 Mar 2017
Q2 2015 -$21.1M -$5.68M -$2.04M -55.9% 01 Apr 2015 30 Jun 2015 10-K 10 Mar 2017
Q1 2015 -$19.1M -$4.69M -$1.31M -38.6% 01 Jan 2015 31 Mar 2015 10-K 10 Mar 2017
Q4 2014 -$17.7M -$4.17M -$2.08M -99.3% 01 Oct 2014 31 Dec 2014 10-K 11 Mar 2016
Q3 2014 -$15.7M -$6.55M -$1.97M -43.1% 01 Jul 2014 30 Sep 2014 10-K 11 Mar 2016
Q2 2014 -$13.7M -$3.65M -$8.98M -168% 01 Apr 2014 30 Jun 2014 10-K 11 Mar 2016
Q1 2014 -$4.71M -$3.38M -$751K -28.5% 01 Jan 2014 31 Mar 2014 10-K 11 Mar 2016
Q4 2013 -$3.96M -$2.09M 01 Oct 2013 31 Dec 2013 10-K 11 Mar 2016
Q3 2013 -$4.58M 01 Jul 2013 30 Sep 2013 10-Q 10 Nov 2014
Q2 2013 $5.34M 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014
Q1 2013 -$2.63M 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014

Tvardi Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$70.9M +$47.6M +40.2% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025
2023 -$119M -$33M -38.7% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025
2022 -$85.5M +$2.97M +3.36% 01 Jan 2022 31 Dec 2022 10-K 11 Mar 2025
2021 -$88.4M -$96.9M -1152% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2024
2020 $8.41M +$115M 01 Jan 2020 31 Dec 2020 10-K 06 Mar 2023
2019 -$106M -$32.4M -43.7% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022
2018 -$74M -$15.9M -27.3% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021
2017 -$58.1M -$845K -1.48% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020
2016 -$57.3M -$32.6M -132% 01 Jan 2016 31 Dec 2016 10-K 12 Mar 2019
2015 -$24.7M -$6.95M -39.1% 01 Jan 2015 31 Dec 2015 10-K 15 Mar 2018
2014 -$17.7M -$13.8M -348% 01 Jan 2014 31 Dec 2014 10-K 10 Mar 2017
2013 -$3.96M +$2.31M +36.8% 01 Jan 2013 31 Dec 2013 10-K 11 Mar 2016
2012 -$6.27M 01 Jan 2012 31 Dec 2012 10-K 27 Mar 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.